Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

Last updated: February 13, 2025
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Completed

Phase

N/A

Condition

Brain Metastases

Neoplasm Metastasis

Treatment

early 18F-FDOPA uptake

Clinical Study ID

NCT05762172
PI2022_843_0055
  • Ages > 18
  • All Genders

Study Summary

Contrast-enhanced magnetic resonance imaging is the most widely used examination for detecting the presence of brain metastasis. Functional sequences such as perfusion weighted imaging makes it possible to differentiate tumor recurrence from cerebral radionecrosis. However, this imaging technique may exhibit limitations, especially for brain lesions consisting of a mixture of necrotic tissue and tumor progression or depending on the location of the lesion in the brain. The use of 18F-DOPA PET is another option available to oncologists. Many studies on gliomas showed the superiority of this imaging technique over contrast-enhanced MRI. However, this imaging solution has been very poorly studied for brain metastases. The new PET technology equiped with silicon detectors makes it possible to obtain greater sensitivities than those of previous generations. It also make possible to obtain images in very short acquisition times. After injection, the hardware allows to obtain the perfusion kinetics of the lesion thanks to a very short temporal sampling (i.e. three seconds).

The main objective of this pilot study is to evaluate the association between early activity measurements (< 4 minutes post-injection) of 18F-FDOPA in PET and the differential diagnosis between radionecrosis and recurrence of cerebral metastases treated by radiotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient referred for cerebral 18F-FDOPA PET examination prescribed as part of hisusual medical care for brain metastasis

  • Age ≥ 18 years old

  • Affiliation to a social security program

  • Ability of the subject to understand and express opposition

Exclusion

Exclusion Criteria:

  • Age under 18

  • Person under guardianship or curators

  • Pregnant woman

Study Design

Total Participants: 8
Treatment Group(s): 1
Primary Treatment: early 18F-FDOPA uptake
Phase:
Study Start date:
February 01, 2022
Estimated Completion Date:
November 11, 2024

Connect with a study center

  • CHU Amiens

    Amiens, Picardie 80054
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.